1Shipp MA,Mauch PM,Harris NL. Non-Hodgkin'slymphomas In:Devita VT Jr,Hellmens,Rosenberg SA eds.Cancer,Principles and practice ofoncology.eds,philadelphia, New Yor：Lippincott-Raven,1977，2164-2167.
2O′Reilly SE,Klimo p,connors JM.The evolving role of etoposide in the managementof lymphomas and Hodgkin's disease[J].Cancer,1991，67(1 suppl):271-273.
2O'Reilly SE, Klimo P, Connors JM. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease[J].Cancer, 1991, 67(1 suppl): 271-273
3Mohammad RM, Wall NR, Dutcher JA, et al. The addiuon of bryostatin 1 to cyclophosphamide, doxombicin, vincristine, and prednisone (GHOP) chemotherapy improves response in a GHOP-resistant human diffuse Large cell lymphoma xenograft model[J]. Clin Cancer Res, 2000, 6(12): 4950-4956
6Wilder DD, Ogden JL, Jain VK, et al. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophos-phamide and prednisone(EPOCH) in patients with relapsed non-Hodgkin's lymphoma[J]. Glin Lymphoma, 2001, 1(4): 285-292
7Jin SH,Kim TI,Han DS,et al. Thalidomide suppresses the interleukin 1 beta-induced NFkappaB signaling pathway in colon cancer cells[J]. Ann N Y Acad Sei,2002,973:414-418.
8Dal Lago L,Riehter MF,Cancela Al,et al. Phase Ⅱ trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer [ J ]. Invest New Drugs, 2003,21 (3) : 359 - 366.
9Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human in munodeficieney virus type Ⅰ and M tube rculosis infection[J]. J Acquir Immune Deflcsyndr hum Petrovirol, 1996,11 : 247 - 257.
10Bruera E,Neumann CM,Pituskin E,et al. Thalidamide in patients with cachexia due to terminal cancer preliminary report[J]. Ann Oncol, 1999, 10:857 -859.
